Refine
Year of publication
Document Type
- Article (5140)
- Doctoral Thesis (1478)
- Part of Periodical (210)
- Conference Proceeding (164)
- Preprint (164)
- Book (85)
- Contribution to a Periodical (63)
- Review (38)
- Working Paper (22)
- Part of a Book (16)
Language
Has Fulltext
- yes (7392) (remove)
Keywords
- inflammation (80)
- COVID-19 (58)
- SARS-CoV-2 (48)
- apoptosis (38)
- glioblastoma (38)
- Inflammation (37)
- cancer (37)
- breast cancer (34)
- autophagy (29)
- prostate cancer (27)
Institute
- Medizin (7392) (remove)
Biomedinformatics: A New Journal for the New Decade to Publish Biomedical Informatics Research
(2021)
With this volume, the peer-reviewed open access journal Biomedinformatics published online on the website https://www.mdpi.com/journal/biomedinformatics, and bearing the current International Standard Serial Number ISSN 2673-7426 enters the scientific community. At the beginning of the 3rd decade of the 21st century, this new journal is dedicated to research reports in the field of biomedical informatics. Biomedinformatics appears at a time when computational methods have reached clinical practice and the transformation to digital medicine is accelerating. Both digitized healthcare and bioinformatics-based research is producing and benefiting from increasingly complex data. This requires the development of tools and methods to extract information from these data and translate it into new knowledge. While biomedical research continues to require clinical and experi- mental data collection, digital healthcare research has clearly evolved from a collection of supporting methods to an equivalent scientific approach, enabling a paradigm shift from almost exclusively hypothesis-driven approaches to increasingly data-driven biomedical research. Indeed, computational science is a rapidly growing multidisciplinary field that uses advanced computational capabilities to understand and solve complex problems by applying new methods of computational intelligence, machine learning, and advanced statistics [1].
Objective: This study was undertaken to identify temporal encephaloceles (TEs) and examine their characteristics in patients with temporal lobe epilepsy (TLE) and ex- tratemporal lobe epilepsy (ETLE), as well as in asymptomatic cases.
Methods: Four hundred fifty-eight magnetic resonance imaging scans were exam- ined retrospectively to identify TE in 157 patients with TLE, 150 patients with ETLE, and 151 healthy controls (HCs).
Results: At least one TE was identified in 9.6% of the TLE patients (n = 15, 95% confidence interval [CI] = 5.3%–15.3%), in 3.3% of patients with ETLE (n = 5, 95% CI = 1.1%–7.6%), and in 2.0% of the HCs (n = 3, 95% CI = .4%–5.7%), indicating a significantly higher frequency in patients with TLE compared to ETLE and HC sub- jects (p = .027, p = .005). Examining the characteristics of TEs in both asymptomatic and epilepsy patients, we found that TEs with a diameter of less than 6.25 mm were more likely to be asymptomatic, with a sensitivity of 91.7% and a specificity of 73.3% (area under the curve = .867, 95% CI = .723–1.00, p = .001).
Significance: Temporal encephaloceles may occur without presenting any clinical symp- toms. Patients with TLE show a higher frequency of TEs compared to the ETLE and HC groups. According to our study, TE size could be used to suggest potential epileptogenicity.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the acute respiratory disease COVID-19, which has become a global concern due to its rapid spread. The common methods to monitor and quantitate SARS-CoV-2 infectivity in cell culture are so far time-consuming and labor-intensive. Using the Sleeping Beauty transposase system, we generated a robust and versatile cellular infection model that allows SARS-CoV-2 infection experiments compatible for high-throughput and live cell imaging. The model is based on lung derived A549 cells, which show a profound interferon response and convenient cell culture characteristics. ACE2 and TMPRSS2 were introduced for constitutive expression (A549-AT). Subclones with varying levels of ACE2/TMPRSS2 were screened for optimal SARS-CoV-2 susceptibility. Furthermore, extensive evaluation demonstrated that SARS-CoV-2 infected A549-AT cells were distinguishable from mock-infected cells and already showed approximately 12 h post infection a clear signal to noise ratio in terms of cell roughness, fluorescence and a profound visible cytopathic effect. Moreover, due to the high transfection efficiency and proliferation capacity, Sleeping Beauty transposase-based overexpression cell lines with a second inducible fluorescence reporter cassette (eGFP) can be generated in a very short time, enabling the investigation of host and restriction factors in a doxycycline-inducible manner. Thus, the novel model cell line allows rapid and sensitive monitoring of SARS-CoV-2 infection and the screening for host factors essential for viral replication. HIGHLIGHTS: Sleeping Beauty transposon-based cellular system was used to generate a highly susceptible cell line for monitoring SARS-CoV-2 infection; The versatile model cell line A549-AT is suitable for rapid and sensitive high-throughput assays; Additional gene specific expression cassettes allow the screening for compounds and cellular factors limiting SARS-CoV-2 replication.
Treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute leukemia (Ph+ ALL) has been revolutionized with the advent of tyrosine kinase inhibitors (TKIs). Most patients with CML achieve long-term survival similar to individuals without CML due to treatment with TKIs not only in frontline but also in further lines of therapy. The third-generation TKI ponatinib has demonstrated efficacy in patients with refractory CML and Ph+ ALL. Ponatinib is currently the most potent TKI in this setting demonstrating activity against T315I mutant clones. However, ponatinib’s safety data revealed a dose-dependent, increased risk of serious cardiovascular (CV) events. Guidance is needed to evaluate the benefit–risk profile of TKIs, such as ponatinib, and safety measures to prevent treatment-associated CV events. An expert panel of German hematologists and cardiologists summarize current evidence regarding ponatinib’s efficacy and CV safety profile. We propose CV management strategies for patients who are candidates for ponatinib.
Alkylglycerol monooxygenase (AGMO) is a tetrahydrobiopterin (BH4)-dependent enzyme with major expression in the liver and white adipose tissue that cleaves alkyl ether glycerolipids. The present study describes the disclosure and biological characterization of a candidate compound (Cp6), which inhibits AGMO with an IC50 of 30–100 µM and 5–20-fold preference of AGMO relative to other BH4-dependent enzymes, i.e., phenylalanine-hydroxylase and nitric oxide synthase. The viability and metabolic activity of mouse 3T3-L1 fibroblasts, HepG2 human hepatocytes and mouse RAW264.7 macrophages were not affected up to 10-fold of the IC50. However, Cp6 reversibly inhibited the differentiation of 3T3-L1 cells towards adipocytes, in which AGMO expression was upregulated upon differentiation. Cp6 reduced the accumulation of lipid droplets in adipocytes upon differentiation and in HepG2 cells exposed to free fatty acids. Cp6 also inhibited IL-4-driven differentiation of RAW264.7 macrophages towards M2-like macrophages, which serve as adipocyte progenitors in adipose tissue. Collectively, the data suggest that pharmacologic AGMO inhibition may affect lipid storage.
Simple Summary:
CDK9, in combination with Cyclin T1, is one of the major regulators of RNA Polymerase II mediated productive transcription of critical genes in any cell. The activity of CDK9 is significantly up-regulated in a wide variety of cancer entities, to aid in the overexpression of genes responsible for the regulation of functions, which are beneficial to the cancer cells, like proliferation, survival, cell cycle regulation, DNA damage repair and metastasis. Enhanced CDK9 activity, therefore, leads to poorer prognosis in many cancer types, offering the rationale to target it using small-molecule inhibitors. Several, increasingly specific inhibitors, have been developed, some of which are presently in clinical trials. Other approaches being tested involve combining inhibitors against CDK9 activity with those against CDK9’s upstream regulators like BRD4, SEC and HSP90; or downstream effectors like cMYC and MCL-1. The inhibition of CDK9’s activity holds the potential to be a highly effective anti-cancer therapeutic.
Abstract:
Cyclin Dependent Kinase 9 (CDK9) is one of the most important transcription regulatory members of the CDK family. In conjunction with its main cyclin partner—Cyclin T1, it forms the Positive Transcription Elongation Factor b (P-TEFb) whose primary function in eukaryotic cells is to mediate the positive transcription elongation of nascent mRNA strands, by phosphorylating the S2 residues of the YSPTSPS tandem repeats at the C-terminus domain (CTD) of RNA Polymerase II (RNAP II). To aid in this process, P-TEFb also simultaneously phosphorylates and inactivates a number of negative transcription regulators like 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) Sensitivity-Inducing Factor (DSIF) and Negative Elongation Factor (NELF). Significantly enhanced activity of CDK9 is observed in multiple cancer types, which is universally associated with significantly shortened Overall Survival (OS) of the patients. In these cancer types, CDK9 regulates a plethora of cellular functions including proliferation, survival, cell cycle regulation, DNA damage repair and metastasis. Due to the extremely critical role of CDK9 in cancer cells, inhibiting its functions has been the subject of intense research, resulting the development of multiple, increasingly specific small-molecule inhibitors, some of which are presently in clinical trials. The search for newer generation CDK9 inhibitors with higher specificity and lower potential toxicities and suitable combination therapies continues. In fact, the Phase I clinical trials of the latest, highly specific CDK9 inhibitor BAY1251152, against different solid tumors have shown good anti-tumor and on-target activities and pharmacokinetics, combined with manageable safety profile while the phase I and II clinical trials of another inhibitor AT-7519 have been undertaken or are undergoing. To enhance the effectiveness and target diversity and reduce potential drug-resistance, the future of CDK9 inhibition would likely involve combining CDK9 inhibitors with inhibitors like those against BRD4, SEC, MYC, MCL-1 and HSP90.
Die vorliegende Studie befasst sich mit dem Einfluss minimalinvasiver Zugangswege zur Mitralklappe auf den Herzrhythmus, den Erfolg einer perioperativ durchgeführten Ablation und die postoperative Notwendigkeit eines Herzschrittmachers.
Mitralklappenvitien und deren herzchirurgische Versorgung sind in vielen Fällen mit präoperativ bestehendem oder postoperativ neu auftretendem Vorhofflimmern assoziiert. In den vergangenen Jahrzehnten haben sich neben der medikamentösen Therapie des Vorhofflimmerns und der durch die Mitralklappeninsuffizienz induzierten Herzinsuffizienz verschiedene minimalinvasive chirurgische Zugangswege zur Mitralklappe sowie Ablationsverfahren etabliert und einen kurativen Therapieansatz gebildet.
Die Ablation im Zuge einer Mitralklappenchirurgie ist zu einem alltäglich durchgeführten Verfahren geworden.
Neu auftretendes Vorhofflimmern im Rahmen der Mitralklappenchirurgie kann perioperativ begrenzt sein und konvertiert häufig innerhalb der ersten 6 Wochen spontan in den Sinusrhythmus. Es geht aber mit einer erhöhten Mortalität und Hospitalisierungszeit einher. Das neu auftretende Vorhofflimmern kann jedoch auch persistieren oder erst im Langzeitverlauf entstehen. Auch die Notwendigkeit eines Herzschrittmachers kann durch Mitralklappeneingriffe insbesondere mit additiver Ablation aufgrund der anatomischen Gegebenheiten erhöht sein.
In unserer Arbeit ist von Interesse, ob sich die unten genannten Zugangswege im Hinblick auf das Neuauftreten von Vorhofflimmern im Langzeitverlauf, die Vorhofflimmerrezidivrate nach Ablation und die Schrittmacherrate mit und ohne durchgeführte Ablation unterscheiden.
Die vorliegende Studie umfasst alle Mitralklappenoperationen, die zwischen 1998 und 2015 in der Klinik für Thorax-, Herz- und thorakale Gefäßchirurgie der Universitätsklinik Frankfurt am Main über die folgenden drei minimalinvasiven Zugangswege, durchgeführt wurden: Gruppe A bildeten 300 Patienten, die im genannten Zeitraum über eine anterolaterale Minithorakotomie mittels Chitwood-Klemme operiert wurden. Gruppe B bestand aus 687 Patienten, die über eine partielle obere Sternotomie mit superiorem transseptalem Zugang operiert wurden. Die 219 Patienten, bei denen eine partielle obere Sternotomie mit transcavalem Zugang angewandt wurde, bildeten Gruppe C.
Die Auswertung erfolgte anhand von Patientenakten, internen und externen Untersuchungsbefunden und eines standardisierten Fragebogens im Follow-up. Es erfolgte eine zweite Auswertung nach Propensity Matching, um präoperative signifikante Unterschiede der Gruppen zu egalisieren.
Im Ergebnis konnte in unserer Studie gezeigt werden, dass die atriale Inzision einen entscheidenden Einfluss auf den Ablationserfolg sowie auf die Schrittmacherinzidenz hat. Bekannt war dabei ein höheres Risiko für postoperatives Vorhofflimmern und Schrittmacherimplantationen aufgrund der anatomischen Gegebenheiten bei Gruppe B. Dass jedoch Gruppe C ein signifikant noch höheres Risiko für Schrittmacherimplantationen mit sich bringt, war überraschend und ist derzeit nicht in der Literatur beschrieben.
In der multivariaten Analyse nach Matching waren Gruppe C, eine additive Ablation und das Alter signifikante unabhängige Prädiktoren für Schrittmacherimplantationen. In der logistischen Regression war Gruppe A ein unabhängiger Prädiktor für den Ablationserfolg zum Zeitpunkt der Entlassung. In der Langzeitbeobachtung trat Gruppe C an Stelle von Gruppe A, möglicherweise aufgrund der bei Gruppe A vorliegenden längsten Follow-up-Zeit. Wie schon in der vorliegenden Literatur diskutiert waren auch in unserer Auswertung hohes Alter und eine präoperative linksatriale Vergrößerung unabhängige Prädiktoren für den langfristigen Ablationserfolg.
Es bedarf weiterer vergleichender Studien mit einheitlichen Follow-up-Zeiten, um die hier gezeigten Ergebnisse zu überprüfen. Insbesondere der transcavale Zugang, der sich im negativen Sinne auf die Zahl der Schrittmacherimplantationen auszuwirken scheint, gibt Anlass für weitere Untersuchungen.
Popular media now often present 3D printing as a widely employed technology for the production of dental prostheses. This article aims to show, based on factual information, to what extent 3D printing can be used in dental laboratories and dental practices at present. It attempts to present a rational evaluation of todays´ applications of 3D printing technology in the context of dental restorations. In addition, the article discusses future perspectives and examines the ongoing viability of traditional dental laboratory services and manufacturing processes. It also shows which expertise is needed for the digital additive manufacturing of dental restorations.
Survival following relapse in children with Acute Myeloid leukemia: a report from AML-BFM and COG
(2021)
Simple Summary: Acute myeloid leukemia in children remains a difficult disease to cure despite intensive therapies that push the limits of tolerability. Though the intent of initial therapy should be the prevention of relapse, about 30% of all patients experience a relapse. Hence, relapse therapy remains critically important for survival. This retrospective analysis of two large international study groups (COG and BFM) was undertaken to describe the current survival, response rates and clinical features that predict outcomes. We demonstrate that children with relapsed AML may be cured with cytotoxic therapy followed by HSCT. High-risk features at initial diagnosis and early relapse remain prognostic for post-relapse survival. Current response criteria are not aligned with the standards of care for children, nor are the count recovery thresholds meaningful for prognosis in children with relapsed AML. Our data provide a new baseline for future treatment planning and will allow an updated stratification in upcoming studies.
Abstract: Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We evaluated survival, response and prognostic variables following relapse in independent cooperative group studies conducted by COG and the population-based AML-BFM study group. BFM included 197 patients who relapsed after closure of the last I-BFM relapse trial until 2017, while COG included 852 patients who relapsed on the last Phase 3 trials (AAML0531, AAML1031). Overall survival at 5 years (OS) was 42 ± 4% (BFM) and 35 ± 2% (COG). Initial high-risk features (BFM 32 ± 6%, COG 26 ± 4%) and short time to relapse (BFM 29 ± 4%, COG 25 ± 2%) predicted diminished survival. In the BFM dataset, there was no difference in OS for patients who had a complete remission with full hematopoietic recovery (CR) following post-relapse re-induction compared to those with partial neutrophil and platelet recovery (CRp and CRi) only (52 ± 7% vs. 63 ± 10%, p = 0.39). Among 90 patients alive at last follow-up, 87 had received a post-relapse hematopoietic stem cell transplant (HSCT). OS for patients with post-relapse HSCT was 54 ± 4%. In conclusion, initial high-risk features and early relapse remain prognostic. Response assessment with full hematopoietic recovery following initial relapse therapy does not predict survival. These data indicate the need for post-relapse risk stratification in future studies of relapse therapies.